Back to Trials
NCT07410117PHASE3Recruiting

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Regeneron Pharmaceuticals

Start Date

3/9/2026

Completion Date

5/6/2030

Summary

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Eligibility Criteria

Age Range: 18 years to No maximum

Key Inclusion Criteria: 1. Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol 2. Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol 3. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention Key Exclusion Criteria: 1. Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy) 2. Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma 3. Has a primary brain tumor or brain metastases as described in the protocol 4. Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period 5. Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Interventions

DRUG

REGN7508

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Cancer-Associated Thrombosis (CAT)

Locations

Bioresearch Partner- Hialeah Hospital

Hialeah, Florida 33013

United States

Helios Clinical Research

North Miami Beach, Florida 33169

United States

El Paso Medical Research Institute (Medresearch Inc)

El Paso, Texas 79902

United States

LTD High Technology Hospital Medcenter

Batumi, Adjara 6000

Georgia

Krystyna Kiel Oncology Center

Kutaisi, Imereti 4600

Georgia

American Hospital Tbilisi

Tbilisi, 0102

Georgia

Llc Todua Clinic

Tbilisi, 0112

Georgia

Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

Tbilisi, 0144

Georgia

Institute of Clinical Oncology

Tbilisi, 0159

Georgia

JSC Evex Hospitals - Caraps Medline

Tbilisi, 0179

Georgia

LTD Cancer Research Centre

Tbilisi, 0179

Georgia

Caucasus Medical Centre

Tbilisi, 0186

Georgia

Yamaguchi University Hospital

Ube, Yamaguchi 755-8505

Japan